Division of Human Nutrition & Health, Wageningen University, 6708 WE Wageningen, The Netherlands.
Business Unit Bioscience, Wageningen Research, 6708 PB Wageningen, The Netherlands.
Nutrients. 2021 Jan 18;13(1):260. doi: 10.3390/nu13010260.
The increased usage of alternative Ayurvedic treatments as potential health-beneficial therapies emphasizes the importance of studying its efficacy in sound placebo-controlled intervention trials. An example of such a traditional Ayurvedic herbal preparation is Mohana Choorna, a mixture composed of 20 different herbs and used to prevent and treat type 2-diabetes (T2D). We studied the efficacy of "Mohana Choorna" on T2D-related parameters in subjects with impaired glucose tolerance. In a double blind, placebo-controlled cross-over trial, 19 overweight (BMI > 27 kg/m) subjects aged 50-70 years with an impaired glucose tolerance received two four-week interventions, i.e., herbal or placebo with a four-week wash-out between interventions. HbA1c, glucose, insulin, triglycerides, cholesterol, blood pressure and augmentation index were measured before and after both interventions at fasting and during a glucose tolerance test. After both interventions, urine was collected to measure treatment exposure using LCMS-based metabolomics and whole genome gene-expression in adipose tissue of 13 subjects. The herbal intervention did not affect plasma glucose triglycerides, cholesterol, blood pressure or the augmentation index but showed a trend towards an increased insulin, HOMA-IR and postprandial insulin levels ( = 0.054, = 0.056 and = 0.095 respectively). An increase in expression of inflammation-related gene sets in adipose tissue was observed after the herbal intervention compared to placebo. Urine metabolomic analysis did not reveal a correlation of the presence of specific plant metabolites with "health markers". Our findings suggest that there is no substantiating evidence to claim that four weeks' use of the Ayurvedic herbal supplement Mohana Choorna beneficially affects glucose homeostasis.
替代阿育吠陀疗法的使用增加,强调了研究其在合理安慰剂对照干预试验中的疗效的重要性。这种传统的阿育吠陀草药制剂的一个例子是 Mohana Choorna,它是由 20 种不同草药组成的混合物,用于预防和治疗 2 型糖尿病(T2D)。我们研究了“Mohana Choorna”对糖耐量受损患者 T2D 相关参数的疗效。在一项双盲、安慰剂对照交叉试验中,19 名超重(BMI > 27 kg/m)、糖耐量受损、年龄在 50-70 岁的受试者接受了两种为期四周的干预措施,即草药或安慰剂,两种干预措施之间有四周的洗脱期。在两次干预前后,空腹和葡萄糖耐量试验期间测量了 HbA1c、血糖、胰岛素、甘油三酯、胆固醇、血压和增强指数。两次干预后,收集尿液以使用基于 LCMS 的代谢组学和 13 名受试者脂肪组织中的全基因组基因表达来测量治疗暴露。草药干预没有影响血浆葡萄糖、甘油三酯、胆固醇、血压或增强指数,但显示出增加胰岛素、HOMA-IR 和餐后胰岛素水平的趋势(= 0.054,= 0.056 和 = 0.095 分别)。与安慰剂相比,在草药干预后观察到脂肪组织中炎症相关基因集的表达增加。尿液代谢组学分析未发现特定植物代谢物的存在与“健康标志物”之间存在相关性。我们的研究结果表明,没有确凿的证据表明使用阿育吠陀草药补充剂 Mohana Choorna 四周可以有益地影响血糖稳态。